12:00 AM
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Prochymal: Interim Phase II data

Osiris reported interim data from a double-blind, U.S. Phase II trial in 63 newly diagnosed Type I diabetics showing that there was no significant difference between Prochymal and placebo in the rate of disease progression as measured by stimulated C-peptide levels at 1 year. However, the company said there was a trend toward fewer hypoglycemic events for...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >